Preclinical development and characterisation of PP353, a formulation of linezolid for intradiscal administration

Documenti analoghi

• Pharmacokinetics of PP353, a formulation of linezolid for intervertebral disc administration, in patients with chronic low back pain and Modic change Type 1: A first‐in‐human, Phase 1b, open‐label, single‐dose study
  di: Shiva S. Tripathi, et al.
  Pubblicazione: (2024)
• Chondrodystrophic Dogs as a Preclinical Large Animal Model of Discogenic Back Pain
  di: Mary K. Heimann, et al.
  Pubblicazione: (2025)
• Advancing Basic and Preclinical Spine Research: Highlights From the ORS PSRS 7th International Spine Research Symposium
  di: Chitra L. Dahia, et al.
  Pubblicazione: (2026)
• Intradiscal administration of autologous platelet‐rich plasma in patients with Modic type 1 associated low back pain: A prospective pilot study
  di: Soya Kawabata, et al.
  Pubblicazione: (2024)
• Complex In Vivo Motion of the Bovine Tail Provides Unique Insights Into Intervertebral Disc Adaptation
  di: Arthur J. Michalek, et al.
  Pubblicazione: (2025)